The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Concordance in oncogenic alterations between primary and recurrent/metastatic cholangiocarcinoma pairs using targeted next-generation sequencing.
 
Sarah Margaret Helena McIntyre
No Relationships to Disclose
 
William Preston
No Relationships to Disclose
 
Henry S. Walch
No Relationships to Disclose
 
Carlie S. Sigel
No Relationships to Disclose
 
Jeremy Sharib
Stock and Other Ownership Interests - Intellia Therapeutics; Intuitive Surgical
Consulting or Advisory Role - Asensus Surgical
 
Wei Chen
No Relationships to Disclose
 
Michael Lidsky
No Relationships to Disclose
 
Ritika Kundra
Stock and Other Ownership Interests - Pfizer
 
Andrea Cercek
Consulting or Advisory Role - Bayer; G1 Therapeutics; GlaxoSmithKline; Incyte; Janssen; Merck; Seagen
Research Funding - GlaxoSmithKline; Rgenix (Inst); Seagen
 
James J. Harding
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Elevar Therapeutics; Exelixis; Hepion Pharmaceuticals; Imvax; Lilly; Medivir; Merck; QED Therapeutics; Zymeworks
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Codiak Biosciences (Inst); Debiopharm Group (Inst); Genoscience Pharma (Inst); Genoscience Pharma (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Yiviva (Inst); Zymeworks (Inst)
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Adicet Bio; Alnylam; AstraZeneca; Autem Medical; BeiGene; Berry Genomics; Celgene (I); Center for Emerging & Neglected Diseases (CEND) (I); CytomX Therapeutics (I); Eisai; Exelixis; Flatiron Health; Genoscience Pharma; Helio Health; Incyte; Ipsen; Lilly (I); Merck Serono; Nerviano Medical Sciences; QED Therapeutics; Rafael Pharmaceuticals (I); RedHill Biopharma; Roche/Genentech; SERVIER; Silenseed (I); SOBI (I); Vector Health; Yiviva; Yiviva
Research Funding - Agios (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); Bayer (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Flatiron Health (Inst); Genentech/Roche (Inst); Genoscience Pharma (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Silenseed (Inst); Yiviva (Inst)
Travel, Accommodations, Expenses - Polaris
 
Vinod P. Balachandran
Research Funding - Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - Inventors on a patent application related to work on antigen cross-reactivity and on a patent application related to work on neoantigen quality modeling.
 
Jeffrey A. Drebin
Employment - American Regent (I)
Leadership - American Regent (I)
Stock and Other Ownership Interests - Alnylam; Arrowhead Pharmaceuticals; Ions Pharmaceuticals
 
Kevin Soares
No Relationships to Disclose
 
Alice Chia-chi Wei
Honoraria - AstraZeneca Canada; Medtronic
Consulting or Advisory Role - Biosapien; Histosonics
 
T. Peter Kingham
Consulting or Advisory Role - Physicans' Education Resource
Speakers' Bureau - Olympus
 
Michael Ian D'Angelica
No Relationships to Disclose
 
Christine A Iacobuzio-Donahue
Research Funding - Bristol Myers Squibb Foundation
 
Nikolaus Schultz
No Relationships to Disclose
 
William R. Jarnagin
No Relationships to Disclose